Mainehealth

Mainehealth was paid $142.72M by Medicaid between Jan 2018 and Dec 2024, across 887 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 16% of everything it billed.

33Billing provider infoMAINEHEALTH
PORTLAND, ME 04102

33aNPI1760436216assigned 05/20/2006

33bProvider typeEmergency Medicine Physician

28Total paid$142.72M

24GClaims3,045,475

24DCodes billed887

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Emergency Medicine Physician providers in Maine

Rank by total paid#1 of 24

Median peer was paid$14K

This provider vs. median10,409×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official INZANA, LUGENE controls 20+ related entities in our dataset. Read more

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	313,057	$11.54M
2019	341,851	$13.73M
2020	287,677	$12.45M
2021	366,913	$18.25M
2022	407,046	$19.45M
2023	456,478	$23.32M
2024incomplete	872,453	$43.99M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0463	Hospital outpatient clinic visit for assessment and management of a patient	16%	318,820	235,045	$22.73M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	12%	105,207	95,061	$16.59M
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	9.9%	53,833	50,463	$14.09M
J9271	Injection, pembrolizumab, 1 mg	3.9%	825	625	$5.53M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	3.3%	41,466	38,629	$4.65M
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	2.0%	3,064	938	$2.83M
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	1.8%	25,251	21,855	$2.61M
77386		1.8%	11,011	988	$2.57M
J1745	Injection, infliximab, excludes biosimilar, 10 mg	1.7%	1,183	1,086	$2.46M
G0383	Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)	1.7%	15,027	14,403	$2.40M
G0382	Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)	1.5%	17,047	16,416	$2.15M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	1.3%	11,967	7,788	$1.90M

875 more codes

99282	Emergency department visit for the evaluation and management, low to moderate severity	1.3%	22,284	$1.82M
74177	Computed tomography, abdomen and pelvis; with contrast material	1.1%	12,414	$1.56M
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	1.1%	17,230	$1.50M
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	1.0%	3,178	$1.46M
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	<1%	3,755	$1.40M
78815	Positron emission tomography (PET) for limited area imaging	<1%	2,012	$1.26M
71046	Radiologic examination, chest; 2 views	<1%	30,809	$1.19M
77412		<1%	10,407	$1.17M
G0381	Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)	<1%	15,486	$1.15M
95810	Polysomnography; sleep staging with 4 or more additional parameters	<1%	1,880	$1.15M
J0585	Injection, onabotulinumtoxina, 1 unit	<1%	2,871	$1.10M
G0330	Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room	<1%	467	$1.07M
42820	Tonsillectomy and adenoidectomy; younger than age 12	<1%	216	$1.03M
Q9991	Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg	<1%	625	$987K
99213	Doctor's office visit, returning patient (routine)	<1%	34,489	$981K
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	5,032	$930K
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	3,608	$921K
Q5121	Injection, infliximab-axxq, biosimilar, (avsola), 10 mg	<1%	740	$921K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	22,128	$853K
76819	Fetal biophysical profile; without non-stress testing	<1%	9,984	$838K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	7,943	$769K
G0008	Administration of influenza virus vaccine	<1%	25,229	$744K
90870		<1%	6,651	$739K
99214	Doctor's office visit, returning patient (more involved)	<1%	14,317	$733K
96375	Therapeutic injection; each additional sequential IV push	<1%	22,111	$693K
70450	Computed tomography, head or brain; without contrast material	<1%	12,802	$679K
69436	Tympanostomy (requiring insertion of ventilating tube), general anesthesia	<1%	994	$661K
41899	Unlisted procedure, dentoalveolar structures	<1%	3,078	$658K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	6,113	$655K
77334		<1%	1,909	$648K
J2350	Injection, ocrelizumab, 1 mg	<1%	29	$644K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	30,666	$638K
90832	Psychotherapy session, about 30 minutes	<1%	8,428	$631K
96361	Intravenous infusion, hydration; each additional hour	<1%	16,457	$625K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	4,142	$605K
90791	Psychiatric diagnostic evaluation	<1%	7,379	$588K
Q9992	Injection, buprenorphine extended-release (sublocade), greater than 100 mg	<1%	345	$585K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	3,758	$580K
99391	Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year)	<1%	10,247	$580K
99392	Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years)	<1%	9,761	$569K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	7,416	$557K
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	996	$527K
71275	Computed tomographic angiography, chest, with contrast material	<1%	4,932	$498K
90839		<1%	6,719	$487K
70496		<1%	2,873	$479K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	6,466	$456K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	4,544	$423K
99393	Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years)	<1%	6,845	$393K
J2426	Injection, paliperidone palmitate extended release (invega sustenna), 1 mg	<1%	270	$377K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	6,536	$367K
99232	Hospital visit by a doctor, follow-up day	<1%	12,861	$362K
54161		<1%	308	$361K
36430		<1%	1,824	$358K
77336		<1%	5,829	$340K
93010	Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only	<1%	77,969	$331K
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	756	$322K
J2357	Injection, omalizumab, 5 mg	<1%	529	$293K
99394	Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years)	<1%	4,757	$291K
76830	Ultrasound, transvaginal	<1%	3,697	$283K
J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	<1%	418	$274K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	18,734	$272K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	3,614	$267K
93656		<1%	30	$259K
G0009	Administration of pneumococcal vaccine	<1%	8,932	$255K
90834	Psychotherapy session, about 45 minutes	<1%	3,081	$248K
20610		<1%	2,239	$248K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	2,406	$243K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	7,102	$236K
J7298	Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg	<1%	327	$222K
72141		<1%	1,765	$222K
58571		<1%	40	$220K
36902		<1%	316	$219K
77300		<1%	1,396	$219K
99395	Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years	<1%	3,627	$218K
71250		<1%	4,538	$217K
76770		<1%	3,089	$210K
93971		<1%	4,074	$208K
C8929	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography	<1%	1,482	$200K
90677		<1%	4,165	$197K
96415		<1%	4,224	$196K
99233	Hospital visit by a doctor, follow-up day (complex)	<1%	3,896	$196K
97803		<1%	9,144	$195K
71045	Radiologic examination, chest; single view	<1%	6,227	$194K
10060		<1%	1,566	$191K
78431		<1%	310	$186K
70491		<1%	1,383	$185K
93304		<1%	774	$184K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	705	$165K
93308		<1%	1,549	$165K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	16,350	$160K
95782		<1%	230	$158K
76811	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed	<1%	938	$157K
74174		<1%	1,361	$156K
74183		<1%	966	$155K
77063	Screening digital breast tomosynthesis, bilateral	<1%	6,515	$150K
95816		<1%	720	$147K
J0897	Injection, denosumab, 1 mg	<1%	241	$146K
99396	Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years	<1%	2,371	$144K
97802		<1%	3,334	$143K
J0741	Injection, cabotegravir and rilpivirine, 2mg/3mg	<1%	48	$140K
64642		<1%	502	$140K
59025	Fetal non-stress test	<1%	906	$140K
76801		<1%	1,654	$138K
47562		<1%	48	$131K
64483		<1%	391	$130K
90739		<1%	1,093	$130K
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	13,915	$123K
90686		<1%	17,038	$120K
93458		<1%	123	$120K
94060		<1%	797	$120K
77290		<1%	824	$116K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	808	$116K
77066	Tomosynthesis, mammo	<1%	1,690	$115K
64493		<1%	325	$114K
67311		<1%	89	$114K
G0378	Hospital observation service, per hour	<1%	11,440	$114K
70486		<1%	1,111	$114K
52356		<1%	64	$112K
76642		<1%	2,469	$106K
76536		<1%	2,061	$104K
43235		<1%	297	$103K
90792	Psychiatric diagnostic evaluation with medical services	<1%	1,129	$100K
59430		<1%	668	$97K
64635		<1%	130	$96K
90853	Group psychotherapy (other than of a multiple-family group)	<1%	3,302	$96K
90480		<1%	4,571	$94K
90651		<1%	4,450	$94K
96417		<1%	2,425	$91K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	11,975	$91K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	11,984	$91K
J1439	Injection, ferric carboxymaltose, 1 mg	<1%	206	$90K
62323		<1%	336	$89K
64615		<1%	738	$89K
95819		<1%	397	$84K
86900		<1%	10,923	$82K
97162		<1%	4,150	$81K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	59,794	$81K
27130		<1%	15	$80K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	1,000	$77K
96409		<1%	598	$77K
96367		<1%	2,262	$77K
93970		<1%	761	$75K
99188		<1%	3,476	$74K
75561		<1%	233	$70K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	<1%	53	$69K
J0185	Injection, aprepitant, 1 mg	<1%	503	$68K
72197		<1%	264	$66K
77295		<1%	154	$65K
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	843	$64K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	3,240	$63K
77065	Tomosynthesis, mammo	<1%	1,196	$63K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	2,888	$63K
91320		<1%	1,770	$63K
74230		<1%	727	$61K
Q3014	Telehealth originating site facility fee	<1%	4,802	$60K
72100		<1%	3,440	$59K
93798		<1%	980	$59K
97166		<1%	2,863	$58K
J2469	Injection, palonosetron hcl, 25 mcg	<1%	3,558	$58K
92587		<1%	274	$57K
G0108	Diabetes outpatient self-management training services, individual, per 30 minutes	<1%	2,017	$57K
97161		<1%	1,741	$56K
76816	Ultrasound, pregnant uterus, real time with image documentation, follow-up	<1%	6,432	$56K
93880		<1%	754	$54K
99239	Hospital discharge day management, more than 30 minutes	<1%	769	$53K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	2,456	$52K
99222	Initial hospital care, per day, moderate complexity	<1%	826	$52K
80061	Lipid panel	<1%	7,618	$52K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	<1%	44	$50K
93303	Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study	<1%	195	$49K
76825		<1%	158	$49K
77301		<1%	101	$48K
80053	Comprehensive metabolic panel	<1%	85,997	$48K
72158		<1%	386	$48K
96411		<1%	1,160	$48K
94010		<1%	1,910	$47K
C8930	Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision	<1%	174	$47K
27447		<1%	19	$47K
99402		<1%	1,886	$47K
91322		<1%	1,062	$46K
96158		<1%	1,214	$46K
29581		<1%	666	$46K
58301		<1%	239	$45K
G0379	Direct admission of patient for hospital observation care	<1%	41	$45K
31575		<1%	409	$44K
99215	Doctor's office visit, returning patient (complex)	<1%	570	$43K
20611		<1%	420	$43K
93296		<1%	2,705	$42K
95811		<1%	67	$40K
74018		<1%	3,086	$40K
P9016	Red blood cells, leukocytes reduced, each unit	<1%	391	$40K
19083		<1%	37	$39K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	92,474	$39K
J1610	Injection, glucagon hydrochloride, per 1 mg	<1%	587	$38K
G0390	Trauma response team associated with hospital critical care service	<1%	87	$37K
73221		<1%	247	$37K
71271		<1%	662	$36K
77470		<1%	184	$36K
42830		<1%	15	$34K
92557		<1%	1,984	$34K
90670		<1%	4,154	$33K
84443	Thyroid stimulating hormone (TSH)	<1%	11,300	$33K
J9305	Injection, pemetrexed, not otherwise specified, 10 mg	<1%	73	$32K
72125	Computed tomography, cervical spine; without contrast material	<1%	5,919	$31K
90656		<1%	5,470	$31K
87481		<1%	9,921	$31K
73030		<1%	5,058	$30K
94726		<1%	507	$30K
73562		<1%	2,866	$29K
93017		<1%	1,829	$29K
73502		<1%	4,718	$28K
92579		<1%	891	$28K
99381		<1%	451	$28K
86780		<1%	2,708	$28K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	3,707	$27K
52000		<1%	158	$27K
76870		<1%	907	$26K
74178		<1%	157	$26K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	5,692	$26K
76885		<1%	366	$25K
58300		<1%	651	$25K
90847	Family psychotherapy with the patient present, 50 minutes	<1%	208	$25K
90678		<1%	90	$25K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	9,220	$25K
73630		<1%	4,938	$25K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	7,653	$24K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	3,745	$24K
76882		<1%	1,445	$24K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	9,150	$24K
99221		<1%	548	$24K
96110	Developmental screening, with scoring and documentation, per standardized instrument	<1%	3,203	$23K
77280		<1%	391	$23K
72146		<1%	301	$23K
97167		<1%	1,569	$22K
J1437	Injection, ferric derisomaltose, 10 mg	<1%	13	$22K
J0485	Injection, belatacept, 1 mg	<1%	54	$22K
73564		<1%	3,902	$22K
99401		<1%	1,705	$22K
99223	Prolong inpt eval add15 m	<1%	221	$22K
92611		<1%	509	$22K
90732		<1%	698	$21K
62321		<1%	92	$21K
36415	Collection of venous blood by venipuncture	<1%	46,797	$21K
20680		<1%	13	$21K
83036	Hemoglobin; glycosylated (A1C)	<1%	16,506	$20K
17110		<1%	424	$19K
0124A		<1%	1,078	$19K
97163		<1%	1,176	$19K
90734		<1%	1,804	$19K
29405		<1%	128	$18K
70498		<1%	2,809	$18K
11102		<1%	340	$18K
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	<1%	2,580	$18K
80305		<1%	8,121	$17K
93923		<1%	300	$17K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion	<1%	91	$17K
93797		<1%	300	$17K
99406		<1%	2,784	$17K
73610		<1%	4,381	$17K
72040		<1%	1,567	$16K
20550		<1%	104	$16K
90662		<1%	2,124	$16K
D0145	Oral evaluation for a patient under three years of age	<1%	879	$16K
80048	Basic metabolic panel (calcium, ionized)	<1%	27,439	$16K
87511		<1%	5,355	$16K
52332		<1%	13	$15K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	5,425	$15K
36591		<1%	2,452	$15K
97165		<1%	566	$15K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	1,661	$15K
93456		<1%	12	$14K
94664		<1%	262	$14K
64633		<1%	19	$14K
43249		<1%	27	$14K
90619		<1%	1,510	$14K
72082		<1%	828	$14K
95700		<1%	103	$14K
99385		<1%	195	$14K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	26,094	$14K
73110		<1%	3,590	$14K
92610		<1%	593	$13K
43264		<1%	12	$13K
D1206	Topical application of fluoride varnish	<1%	1,091	$13K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	3,715	$13K
73130		<1%	2,850	$13K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	682	$13K
72070		<1%	695	$13K
29075		<1%	71	$13K
90837	Psychotherapy session, about an hour	<1%	139	$13K
87522	Neg quan hep c or qual rna	<1%	1,006	$12K
77080		<1%	246	$12K
0001A		<1%	387	$12K
17250		<1%	147	$12K
0054A		<1%	551	$12K
93975		<1%	79	$11K
87536		<1%	500	$11K
77338		<1%	88	$11K
90746		<1%	458	$11K
88142		<1%	2,260	$11K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	7,632	$11K
G0260	Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography	<1%	39	$11K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	13,062	$10K
73590		<1%	1,784	$10K
99495		<1%	130	$10K
82728		<1%	3,979	$10K
77072		<1%	161	$10K
96127		<1%	1,563	$9K
96401		<1%	413	$9K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	1,075	$9K
G0384	Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)	<1%	43	$9K
P9040	Red blood cells, leukocytes reduced, irradiated, each unit	<1%	48	$9K
95714		<1%	15	$9K
C1769	Guide wire	<1%	7,236	$9K
83655		<1%	3,090	$9K
73560		<1%	1,443	$9K
86870		<1%	65	$8K
85027		<1%	21,567	$8K
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s)	<1%	26	$8K
96152		<1%	141	$8K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	420	$8K
73552		<1%	1,445	$8K
82607		<1%	3,093	$8K
J2704	Injection, propofol, 10 mg	<1%	44,655	$8K
99403		<1%	168	$8K
86480		<1%	382	$8K
92582		<1%	154	$8K
99383		<1%	120	$8K
76881		<1%	121	$8K
0002A		<1%	223	$8K
90716		<1%	2,492	$8K
99407		<1%	742	$8K
99404		<1%	127	$7K
75574		<1%	82	$7K
88342		<1%	3,618	$7K
93242		<1%	615	$7K
95911		<1%	15	$7K
81025		<1%	8,920	$7K
C8908	Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral	<1%	26	$7K
29065		<1%	34	$7K
99205	Prolong outpt/office vis	<1%	68	$7K
76604		<1%	494	$7K
87086	Culture, bacterial; quantitative colony count, urine	<1%	15,537	$7K
92552		<1%	167	$6K
85610		<1%	13,478	$6K
95909		<1%	65	$6K
82746		<1%	2,416	$6K
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	244	$6K
86803		<1%	2,533	$6K
76775		<1%	633	$6K
72170		<1%	1,003	$6K
86481		<1%	180	$6K
11981		<1%	94	$6K
76815	Ultrasound, pregnant uterus, real time with image documentation, limited	<1%	5,192	$6K
97116		<1%	3,098	$6K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	239	$6K
84702		<1%	3,401	$6K
12001		<1%	1,079	$6K
93225		<1%	214	$5K
99203	Doctor's office visit, new patient (routine)	<1%	121	$5K
88184		<1%	80	$5K
11104		<1%	48	$5K
90673		<1%	78	$5K
86706		<1%	1,634	$5K
69210		<1%	318	$5K
97535	Self-care/home management training, each 15 minutes	<1%	3,048	$5K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	13	$5K
73140		<1%	1,387	$5K
D1208	Topical application of fluoride, excluding varnish	<1%	410	$5K
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	5,109	$5K
G0010	Administration of hepatitis b vaccine	<1%	251	$5K
83735		<1%	17,743	$5K
57454		<1%	15	$5K
96150		<1%	79	$5K
93298		<1%	210	$5K
83550		<1%	3,132	$5K
J1750	Injection, iron dextran, 50 mg	<1%	17	$5K
72156		<1%	14	$4K
70544		<1%	42	$4K
C1887	Catheter, guiding (may include infusion/perfusion capability)	<1%	1,932	$4K
86704		<1%	1,331	$4K
73521		<1%	229	$4K
58100		<1%	42	$4K
99204	Doctor's office visit, new patient (more involved)	<1%	57	$4K
87340		<1%	2,659	$4K
74240		<1%	29	$4K
C1725	Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)	<1%	2,418	$4K
93246		<1%	393	$4K
73080		<1%	1,172	$4K
30140		<1%	20	$4K
82950		<1%	896	$4K
72131		<1%	149	$4K
0081A		<1%	147	$4K
96156		<1%	74	$4K
86850		<1%	10,860	$4K
83970		<1%	387	$4K
96402		<1%	256	$4K
83540		<1%	3,299	$4K
84439		<1%	1,842	$4K
93922		<1%	548	$4K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	4,349	$4K
0072A		<1%	186	$4K
64400		<1%	23	$4K
51700		<1%	57	$3K
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	4,016	$3K
G0101	Cervical or vaginal cancer screening; pelvic and clinical breast examination	<1%	67	$3K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	43,385	$3K
73070		<1%	592	$3K
69209		<1%	274	$3K
95910		<1%	16	$3K
72081		<1%	129	$3K
73700		<1%	55	$3K
G0399	Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation	<1%	32	$3K
G0297	Low dose ct scan (ldct) for lung cancer screening	<1%	120	$3K
11982		<1%	15	$3K
90473		<1%	132	$3K
17311		<1%	16	$3K
88341		<1%	2,152	$3K
84703		<1%	15,085	$3K
99238	Hospital discharge day management, 30 minutes or less	<1%	63	$3K
96523		<1%	146	$3K
87070		<1%	11,788	$3K
96376		<1%	5,529	$3K
0052A		<1%	86	$3K
92652		<1%	20	$3K
88307		<1%	2,514	$3K
86003		<1%	106	$3K
73600		<1%	766	$3K
87186		<1%	6,206	$3K
J1756	Injection, iron sucrose, 1 mg	<1%	3,450	$3K
0082A		<1%	86	$3K
97760		<1%	448	$3K
86787		<1%	652	$3K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	16	$3K
93926		<1%	104	$3K
0071A		<1%	167	$3K
86901		<1%	11,110	$3K
81001		<1%	18,358	$3K
83880		<1%	5,965	$3K
84403		<1%	233	$3K
86923		<1%	829	$2K
73090		<1%	866	$2K
83021		<1%	361	$2K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	336	$2K
J1644	Injection, heparin sodium, per 1000 units	<1%	18,712	$2K
J0690	Injection, cefazolin sodium, 500 mg	<1%	17,097	$2K
86140		<1%	7,691	$2K
96381		<1%	174	$2K
72110		<1%	144	$2K
87077		<1%	7,360	$2K
31231		<1%	23	$2K
83690		<1%	17,025	$2K
90715		<1%	9,305	$2K
98929		<1%	128	$2K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	<1%	2,147	$2K
84484		<1%	23,568	$2K
Q9957	Injection, perflutren lipid microspheres, per ml	<1%	1,802	$2K
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	<1%	73	$2K
76981		<1%	24	$2K
77387		<1%	163	$2K
0004A		<1%	657	$2K
87517		<1%	96	$2K
90688		<1%	405	$2K
82947		<1%	663	$2K
99234		<1%	52	$2K
90620		<1%	47	$2K
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)	<1%	22	$2K
80178		<1%	1,016	$2K
64447		<1%	186	$2K
96112		<1%	20	$2K
0051A		<1%	58	$2K
80076		<1%	904	$2K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	24,750	$2K
76376		<1%	2,130	$2K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	4,424	$2K
J7325	Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg	<1%	59	$2K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	42,125	$2K
72157		<1%	27	$2K
S9441	Asthma education, non-physician provider, per session	<1%	167	$2K
D0330	Panoramic radiographic image	<1%	49	$2K
81003		<1%	22,088	$2K
11900		<1%	50	$2K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	381	$2K
87468		<1%	733	$2K
93356		<1%	1,631	$2K
87469		<1%	732	$2K
J1170	Injection, hydromorphone, up to 4 mg	<1%	21,279	$2K
82043		<1%	2,373	$1K
C1776	Joint device (implantable)	<1%	475	$1K
C1726	Catheter, balloon dilatation, non-vascular	<1%	1,380	$1K
00170	Anesthesia for intraoral procedures, including biopsy	<1%	13	$1K
87040		<1%	5,048	$1K
98928		<1%	364	$1K
82784		<1%	533	$1K
C1729	Catheter, drainage	<1%	453	$1K
86618		<1%	1,246	$1K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	31,945	$1K
99231	Subsequent hospital care, per day, straightforward or low complexity	<1%	58	$1K
93312		<1%	15	$1K
92551		<1%	169	$1K
81000		<1%	5,501	$1K
29515		<1%	13	$1K
84402		<1%	128	$1K
64415		<1%	105	$1K
73000		<1%	138	$1K
99386		<1%	17	$1K
73060		<1%	304	$1K
74221		<1%	18	$1K
90681		<1%	3,921	$1K
77332		<1%	28	$1K
93280		<1%	65	$1K
72050		<1%	18	$1K
92201		<1%	83	$1K
86902		<1%	13	$1K
51702		<1%	78	$1K
71101		<1%	82	$1K
85730		<1%	3,863	$1K
84425		<1%	127	$1K
J1815	Injection, insulin, per 5 units	<1%	7,160	$1K
74220		<1%	16	$1K
12002		<1%	330	$1K
85018		<1%	2,613	$1K
76641		<1%	13	$1K
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	25	$1K
51798		<1%	1,189	$1K
92553		<1%	35	$998.72
96154		<1%	80	$972.93
83993		<1%	105	$964.98
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	5,621	$955.53
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	1,578	$954.63
80074		<1%	184	$946.63
G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous	<1%	126	$943.50
99460		<1%	15	$941.95
80164		<1%	484	$941.67
99382		<1%	15	$935.64
82670		<1%	80	$927.39
84100		<1%	3,914	$926.51
0031A		<1%	33	$925.16
88112		<1%	595	$907.45
95800		<1%	12	$889.37
J3370	Injection, vancomycin hcl, 500 mg	<1%	5,020	$882.47
86360		<1%	156	$878.03
73100		<1%	144	$874.52
98926		<1%	312	$869.35
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	4,251	$868.68
90658		<1%	44	$855.66
74330		<1%	424	$852.38
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	5,347	$828.24
99384		<1%	13	$819.09
88304		<1%	2,435	$810.18
C9399	Unclassified drugs or biologicals	<1%	1,185	$809.93
J2270	Injection, morphine sulfate, up to 10 mg	<1%	7,358	$780.44
82570		<1%	1,626	$778.73
84460		<1%	521	$778.66
99397		<1%	41	$774.56
85660		<1%	398	$772.18
92567		<1%	4,147	$769.15
99173		<1%	399	$766.12
J7120	Ringers lactate infusion, up to 1000 cc	<1%	2,369	$757.79
80069		<1%	241	$731.27
76000		<1%	122	$722.67
86359		<1%	156	$722.60
83001		<1%	112	$712.55
90710		<1%	1,605	$701.00
84153		<1%	142	$693.18
0154A		<1%	54	$692.30
86762		<1%	892	$687.39
C2617	Stent, non-coronary, temporary, without delivery system	<1%	1,236	$682.15
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	20,012	$666.87
70355		<1%	138	$666.07
83605		<1%	5,747	$663.00
93750		<1%	13	$661.17
85652		<1%	3,128	$656.30
86364		<1%	225	$649.35
0003A		<1%	54	$642.66
12011		<1%	439	$640.78
87081		<1%	6,366	$640.52
82805		<1%	2,456	$639.04
29125		<1%	190	$626.30
81002		<1%	11,499	$624.64
C8928	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report	<1%	14	$618.33
17000		<1%	160	$614.50
76937		<1%	879	$603.81
98925		<1%	184	$598.91
73620		<1%	74	$590.30
87205		<1%	4,341	$585.71
86334		<1%	124	$580.45
84146		<1%	66	$571.54
83037		<1%	3,326	$514.92
86038		<1%	147	$500.06
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	132	$498.31
85379		<1%	3,464	$495.83
84156		<1%	1,366	$495.75
90380		<1%	37	$494.55
J2359	Injection, olanzapine, 0.5 mg	<1%	23	$485.68
Q0091	Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory	<1%	36	$484.44
90744		<1%	2,036	$483.20
70360		<1%	26	$472.90
J7060	5% dextrose/water (500 ml = 1 unit)	<1%	562	$451.73
82550		<1%	2,279	$445.99
99443		<1%	19	$430.80
J3475	Injection, magnesium sulfate, per 500 mg	<1%	4,007	$413.49
93325		<1%	2,266	$395.23
92555		<1%	323	$386.53
97810		<1%	180	$381.99
83615		<1%	1,100	$377.56
83921		<1%	115	$377.17
95970		<1%	81	$366.01
A4648	Tissue marker, implantable, any type, each	<1%	252	$364.03
J2785	Injection, regadenoson, 0.1 mg	<1%	927	$357.80
82948		<1%	5,309	$355.96
92550		<1%	58	$354.71
J7042	5% dextrose/normal saline (500 ml = 1 unit)	<1%	17	$333.89
72190		<1%	14	$326.83
72020		<1%	178	$326.68
C1732	Catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping	<1%	46	$316.54
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	7,087	$314.36
87209		<1%	55	$312.80
J3480	Injection, potassium chloride, per 2 meq	<1%	3,447	$307.95
J0780	Injection, prochlorperazine, up to 10 mg	<1%	1,958	$307.74
36600		<1%	47	$307.45
85045		<1%	836	$307.30
76942		<1%	836	$298.68
C1758	Catheter, ureteral	<1%	1,692	$297.78
72192		<1%	15	$294.21
83020		<1%	152	$283.14
84165		<1%	123	$279.08
87206		<1%	711	$278.48
82248		<1%	203	$277.25
96167		<1%	34	$276.66
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	6,001	$275.65
73565		<1%	23	$274.51
98927		<1%	67	$267.92
82533		<1%	46	$263.20
80197		<1%	145	$263.03
82785		<1%	50	$256.83
86708		<1%	52	$251.26
91200		<1%	17	$249.68
97014		<1%	237	$249.41
46600		<1%	92	$240.93
73660		<1%	87	$234.11
J1630	Injection, haloperidol, up to 5 mg	<1%	4,209	$231.48
C1730	Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes)	<1%	67	$216.80
87505		<1%	39	$216.51
85651		<1%	1,025	$209.51
J1650	Injection, enoxaparin sodium, 10 mg	<1%	5,523	$202.14
85007		<1%	1,412	$197.13
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	1,191	$190.86
P9612	Catheterization for collection of specimen, single patient, all places of service	<1%	189	$189.28
87529		<1%	153	$186.34
J2060	Injection, lorazepam, 2 mg	<1%	5,376	$182.51
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	440	$182.27
87634		<1%	145	$181.98
96040		<1%	12	$181.74
C1727	Catheter, balloon tissue dissector, non-vascular (insertable)	<1%	466	$181.16
J2720	Injection, protamine sulfate, per 10 mg	<1%	187	$178.18
82105		<1%	54	$174.44
93613		<1%	14	$172.66
87210		<1%	1,642	$171.76
96165		<1%	26	$163.71
G0296	Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making)	<1%	13	$163.08
86431		<1%	117	$161.02
J1790	Injection, droperidol, up to 5 mg	<1%	4,227	$159.42
87177		<1%	55	$154.31
77073		<1%	66	$153.22
83002		<1%	20	$148.16
99152		<1%	1,658	$143.44
83521		<1%	50	$138.25
94729		<1%	1,055	$134.99
88173		<1%	123	$133.16
96164		<1%	26	$130.15
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	275	$129.46
A9555	Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries	<1%	328	$127.92
82330		<1%	50	$124.54
82140		<1%	254	$121.22
J2543	Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)	<1%	2,313	$120.46
77417		<1%	367	$117.92
83721		<1%	53	$116.78
87075		<1%	990	$113.98
84550		<1%	297	$112.47
84450		<1%	88	$110.59
86682		<1%	14	$109.78
82977		<1%	48	$109.60
88313		<1%	187	$108.51
87493		<1%	26	$104.48
84134		<1%	44	$102.13
84132		<1%	814	$101.54
J9045	Injection, carboplatin, 50 mg	<1%	1,311	$101.46
J1920	Injection, labetalol hydrochloride, 5 mg	<1%	203	$100.07
87102		<1%	279	$97.53
J1050	Injection, medroxyprogesterone acetate, 1 mg	<1%	2,388	$97.50
90691		<1%	779	$95.83
J3490	Unclassified drugs	<1%	5,025	$90.97
J0295	Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	<1%	1,647	$89.22
99153	Mod sedat endo service >5yrs	<1%	1,384	$88.99
80175		<1%	104	$88.62
82365		<1%	201	$87.86
J1580	Injection, garamycin, gentamicin, up to 80 mg	<1%	824	$83.88
90723		<1%	87	$82.03
88309		<1%	42	$78.24
80177		<1%	90	$77.41
43273		<1%	43	$73.37
83516		<1%	17	$70.26
90472	Immunization administration, each additional vaccine (list separately)	<1%	16,266	$68.88
J2795	Injection, ropivacaine hydrochloride, 1 mg	<1%	830	$65.30
87116		<1%	170	$64.80
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	6,668	$64.01
82378		<1%	72	$59.88
C9290	Injection, bupivacaine liposome, 1 mg	<1%	792	$58.88
J7070	Infusion, d5w, 1000 cc	<1%	420	$58.80
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	<1%	1,717	$57.03
90632		<1%	852	$55.06
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	<1%	4,716	$50.18
82565		<1%	50	$49.65
87484		<1%	38	$49.12
86663		<1%	15	$46.53
87420		<1%	1,214	$45.60
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	335	$45.49
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	800	$44.44
J0360	Injection, hydralazine hcl, up to 20 mg	<1%	195	$43.45
J2274	Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg	<1%	587	$41.50
89051		<1%	508	$40.78
J1940	Injection, furosemide, up to 20 mg	<1%	2,675	$40.70
G8987	Self care functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	892	$37.86
G8988	Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	893	$37.86
G8989	Self care functional limitation, discharge status, at discharge from therapy or to end reporting	<1%	887	$37.86
87400		<1%	192	$37.80
77002		<1%	171	$37.36
88331		<1%	410	$36.80
J1596	Injection, glycopyrrolate, 0.1 mg	<1%	917	$34.42
84155		<1%	48	$33.76
97804		<1%	153	$32.30
Q9961	High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml	<1%	266	$30.68
J1836	Injection, metronidazole, 10 mg	<1%	566	$27.14
82272		<1%	409	$26.64
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	<1%	1,394	$26.35
82009		<1%	678	$26.19
82150		<1%	15	$25.92
86308		<1%	228	$25.90
83883		<1%	12	$23.20
J1010	Injection, methylprednisolone acetate, 1 mg	<1%	1,275	$23.04
82247		<1%	13	$20.52
J9267	Injection, paclitaxel, 1 mg	<1%	563	$19.83
82044		<1%	353	$17.61
82962		<1%	170	$16.73
36416		<1%	14,808	$16.38
85014		<1%	16	$12.80
87207		<1%	12	$12.26
80306		<1%	194	$11.22
J1805	Injection, esmolol hydrochloride, 10 mg	<1%	55	$9.74
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	<1%	1,114	$9.54
89050		<1%	13	$9.44
85384		<1%	103	$8.68
82040		<1%	15	$7.90
J0736	Injection, clindamycin phosphate, 300 mg	<1%	20	$7.41
J2003	Injection, lidocaine hydrochloride, 1 mg	<1%	1,460	$6.46
J8540	Dexamethasone, oral, 0.25 mg	<1%	4,657	$6.03
84157		<1%	13	$4.25
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	365	$3.76
J3260	Injection, tobramycin sulfate, up to 80 mg	<1%	194	$2.50
C1760	Closure device, vascular (implantable/insertable)	<1%	370	$2.00
93321		<1%	782	$1.52
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	<1%	2,564	$0.36
J2305	Injection, nitroglycerin, 5 mg	<1%	129	$0.05
90697		0%	2,632	$0.00
90698		0%	3,960	$0.00
90717		0%	59	$0.00
91317		0%	56	$0.00
76820		0%	1,095	$0.00
C1759	Catheter, intracardiac echocardiography	0%	65	$0.00
92556		0%	100	$0.00
G8980	Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting	0%	1,250	$0.00
90474		0%	3,815	$0.00
95886		0%	275	$0.00
J1040	Injection, methylprednisolone acetate, 80 mg	0%	157	$0.00
90696		0%	1,550	$0.00
J1030	Injection, methylprednisolone acetate, 40 mg	0%	1,000	$0.00
64494		0%	388	$0.00
76377		0%	85	$0.00
90647		0%	309	$0.00
77001		0%	131	$0.00
90660		0%	29	$0.00
C1781	Mesh (implantable)	0%	229	$0.00
J8501	Aprepitant, oral, 5 mg	0%	449	$0.00
93320		0%	306	$0.00
90381		0%	121	$0.00
96368		0%	780	$0.00
91307		0%	505	$0.00
91315		0%	45	$0.00
C1766	Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away	0%	95	$0.00
11045		0%	109	$0.00
J2372	Injection, phenylephrine hydrochloride (biorphen), 20 micrograms	0%	86	$0.00
C1893	Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away	0%	38	$0.00
C1889	Implantable/insertable device, not otherwise classified	0%	55	$0.00
A9503	Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries	0%	26	$0.00
88185		0%	70	$0.00
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	0%	158	$0.00
91319		0%	55	$0.00
Q2036	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)	0%	27	$0.00
97010		0%	585	$0.00
91305		0%	627	$0.00
J7050	Infusion, normal saline solution, 250 cc	0%	20	$0.00
73120		0%	20	$0.00
G8998	Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting	0%	14	$0.00
C1892	Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away	0%	12	$0.00
A4627	Spacer, bag or reservoir, with or without mask, for use with metered dose inhaler	0%	44	$0.00
99174		0%	66	$0.00
2000F		0%	28	$0.00
91303		0%	32	$0.00
91318		0%	105	$0.00
95885		0%	82	$0.00
J3411	Injection, thiamine hcl, 100 mg	0%	23	$0.00
C1733	Catheter, electrophysiology, diagnostic/ablation, other than 3d or vector mapping, other than cool-tip	0%	15	$0.00
88311		0%	13	$0.00
J0456	Injection, azithromycin, 500 mg	0%	20	$0.00
J2358	Injection, olanzapine, long-acting, 1 mg	0%	16	$0.00
64636		0%	159	$0.00
90700		0%	1,691	$0.00
95874		0%	359	$0.00
90633		0%	5,161	$0.00
17003		0%	67	$0.00
J0744	Injection, ciprofloxacin for intravenous infusion, 200 mg	0%	61	$0.00
78434		0%	193	$0.00
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	1,274	$0.00
90671		0%	1,775	$0.00
90707		0%	2,908	$0.00
97799		0%	1,306	$0.00
A9541	Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries	0%	61	$0.00
91321		0%	1,502	$0.00
J0688	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg	0%	104	$0.00
J1953	Injection, levetiracetam, 10 mg	0%	30	$0.00
90713		0%	1,005	$0.00
G0500	Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate)	0%	251	$0.00
Q2038	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)	0%	154	$0.00
J0670	Injection, mepivacaine hydrochloride, per 10 ml	0%	36	$0.00
J3489	Injection, zoledronic acid, 1 mg	0%	628	$0.00
J0692	Injection, cefepime hydrochloride, 500 mg	0%	100	$0.00
64999		0%	43	$0.00
96159		0%	106	$0.00
J0290	Injection, ampicillin sodium, 500 mg	0%	455	$0.00
76999		0%	12	$0.00
A9575	Injection, gadoterate meglumine, 0.1 ml	0%	283	$0.00
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	0%	1,269	$0.00
90648		0%	1,003	$0.00
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	0%	864	$0.00
64643		0%	381	$0.00
J9190	Injection, fluorouracil, 500 mg	0%	274	$0.00
J2550	Injection, promethazine hcl, up to 50 mg	0%	373	$0.00
90714		0%	126	$0.00
J1171	Injection, hydromorphone, 0.1 mg	0%	706	$0.00
91300		0%	1,027	$0.00
J2919	Injection, methylprednisolone sodium succinate, 5 mg	0%	349	$0.00
91312		0%	694	$0.00
J2401	Injection, chloroprocaine hydrochloride, per 1 mg	0%	42	$0.00
C1874	Stent, coated/covered, with delivery system	0%	155	$0.00
91308		0%	283	$0.00
80348		0%	138	$0.00
J9263	Injection, oxaliplatin, 0.5 mg	0%	39	$0.00
90685		0%	238	$0.00
Q0244	Injection, casirivimab and imdevimab, 1200 mg	0%	14	$0.00
J2004	Injection, lidocaine hcl with epinephrine, 1 mg	0%	307	$0.00
Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg	0%	13	$0.00
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes)	0%	56	$0.00
92504		0%	43	$0.00
G8997	Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	15	$0.00
G8996	Swallowing functional limitation, current status at therapy episode outset and at reporting intervals	0%	14	$0.00
J0153	Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)	0%	12	$0.00
J0640	Injection, leucovorin calcium, per 50 mg	0%	90	$0.00
85049		0%	12	$0.00
96113		0%	18	$0.00
T1013	Sign language or oral interpretive services, per 15 minutes	0%	14	$0.00
64634		0%	19	$0.00
90687		0%	14	$0.00
88312		0%	19	$0.00
80326		0%	16	$0.00
C2625	Stent, non-coronary, temporary, with delivery system	0%	18	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialINZANA, LUGENE (CFO & ASSOCIATE CFO)

Same official

Other billing entities under INZANA, LUGENE

Full network →

Provider	Location	Paid
Mainehealth	Portland, ME	$115.05M
Mainehealth	Biddeford, ME	$70.83M
Mainehealth	Brunswick, ME	$40.06M
Mainehealth	Farmington, ME	$22.62M
Mainehealth	Biddeford, ME	$10.89M
Mainehealth	Falmouth, ME	$6.54M
Mainehealth	Portland, ME	$5.46M
Mainehealth	Scarborough, ME	$5.04M
Mainehealth	Rockport, ME	$4.34M
Mainehealth	Scarborough, ME	$4.16M
Mainehealth	Portland, ME	$4.09M
Mainehealth	Scarborough, ME	$3.94M
Mainehealth	Portland, ME	$3.55M
Mainehealth	Waldoboro, ME	$3.43M
Mainehealth	Scarborough, ME	$3.18M
Mainehealth	Brunswick, ME	$2.77M
Mainehealth	Portland, ME	$2.68M
Mainehealth	Falmouth, ME	$2.10M
Mainehealth	Portland, ME	$1.87M
Mainehealth	Cape Elizabeth, ME	$1.82M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.